Shots:
- GSK has reported P-III (GLISTEN) trial data assessing linerixibat (n=119) vs PBO (n=119) to treat PBC pts (N=238) with cholestatic pruritus; pts could switch to linerixibat in Part B of the trial
- Trial met its 1EP, showing significantly reduced itch per WI-NRS scale in PBC pts, as assessed by monthly itch score, over 24wks.
- Trial also met its key 2EPs, showing rapid & sustained itch relief at Wk. 2 as well as reduced itch-related sleep interference over 24wks., with 56% vs 43% achieving significant itch improvement (WI-NRS ≥3-point reduction) at Wk. 24; data was presented at EASL 2025
Ref: GSK | Image: GSK
Related News:- GSK Receives the MHRA’s Approval for Blenrep (Belantamab Mafodotin) Regimens to Treat R/R Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
